Clínic Barcelona

Simvastatin can lengthen the survival of patients with cirrhosis

Gastroenterology has published a clinical trial promoted and coordinated by Hospital Clínic - IDIBAPS where it is shown that the addition of simvastatin to standard therapy in patients with cirrhosis can lengthen their survival. The article is signed by, among others, Dr. Jaume Bosch, hepatologist at Clínic and head of the research team Liver hemodynamics and portal hypertension of IDIBAPS; Dr. Juan Carlos García-Pagán and Juan González-Abraldes, from the same research group, and Dr. Fernando Torres, director of the IDIBAPS medical statistics platform.